呼和浩特痔疮哪家医院比较好呼和浩特梅花痔疮怎么治疗,新城区肛肠医院治痔疮吗,呼和浩特女生外痔怎么治,呼和浩特市微创混合痔疮手术多少钱,呼市东大肛肠医院点评,呼和浩特市如何治疗内痔疮便血,呼和浩特治疗结缔组织外痔大概要多少钱

LUQA, Malta, Feb. 26 (Xinhua) -- A chartered plane of China Eastern Airlines carrying 272 Chinese evacuees from Libya left Malta for Shanghai on Saturday.The Airbus A330-300 plane took off at 8:20 p.m. local time ( 1920 GMT) from the Malta International Airport, to be followed shortly by another chartered plane of China Eastern Airlines with 278 Chinese evacuees on board.The 550-strong Chinese nationals from a Chinese construction company were among a total of 2,216 people who arrived by a ship from violence-torn Libya at the Grand Harbor in Valletta, capital of Malta, on Saturday.In addition to the 2,216 Chinese nationals, the ship chartered by the Chinese embassy in Malta also carried dozens of citizens of other countries.The vessel, which was the first Maltese ship chartered by the Chinese government to evacuate Chinese nationals, left Libya's Benghazi on Friday.Maltese Deputy Prime Minister and Foreign Minister Tonio Borg, who went aboard the ship, expressed gratitude to the Chinese government for helping to evacuate some Maltese nationals from Libya.Chinese Ambassador to Malta Zhang Keyuan also thanked the Maltese government for its cooperation in the evacuation of Chinese nationals.A 19-day-old baby was among the evacuated Chinese, said a source with the Chinese embassy.China Eastern Airlines will fly four planes every day to the Mediterranean island nation from Feb. 28 to March 10, as part of all-round airborne evacuation missions aimed at taking stranded Chinese citizens back home as soon as possible, according to information from an emergency meeting of the Civil Aviation Administration of China (CAAC) in Beijing on Saturday.

WASHINGTON, May 27 (Xinhua) -- The U.S. Treasury Department said in a report released on Friday that China was not manipulating its currency."In China, since the authorities decided in June 2010 to allow the exchange rate to appreciate in response to market forces, the renminbi (RMB) has appreciated by a total of 5.1 percent against the dollar in nominal terms through the end of April 2011, or at an annual pace of approximately 6.0 percent," noted the semi- annual report on international economic and exchange rate policies.The Treasury said that as inflation in China is significantly higher than it is in the United States, the renminbi has appreciated more rapidly against the dollar on a real, inflation- adjusted basis, at a rate of around 9 percent per year.The delayed report, which was originally scheduled to be sent to the Congress on April 15, finds "no major trading partner of the United States" manipulated its currency during the period covered in the report.The Treasury added that it will continue to "closely monitor" the renminbi appreciation pace.The report also noted that the U.S. economy is recovering from its deepest recession in the post-war period."While recent growth is encouraging, the economy still faces significant challenges," said the report. The number one challenge is still in the labor market.The U.S. unemployment rate, currently at 9.0 percent, is not expected to fall significantly this year.Besides, housing market and long-term fiscal position are " unsustainable," according to the report.In recent remarks, Treasury Secretary Timothy Geithner stated that China is the fastest growing market for U.S. exports. In 2010, U.S. exports to China grew at a pace that was 50 percent higher than the rest of the world.

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.

BEIJING, Jan. 20 (Xinhua) -- China on Thursday announced it had introduced a regulation to better manage state compensation funds. The regulation was signed by Chinese Premier Wen Jiabao Monday and immediately came into effect then.The regulation is aimed to ensure eligible claimants receive state compensation on time and in full.The regulation means governments at all levels must budget for state compensation payouts each year, and if the actual amount of state compensation payouts exceed what is budgeted for, additional funds must be used.The regulation also standardizes the procedure of applying for state compensation.State compensation refers to government pay outs to citizens for damages it has caused them through infringements of their rights.The State Compensation Law of China took effect since 1995.

LOS ANGELES, April 7 (Xinhua) -- Using NASA's Galaxy Evolution Explorer (GEE) satellite, U.S. astronomers are hunting for nearby, hard-to-see stars which could very well be home to the easiest-to-see alien planets, it was announced on Thursday.U.S. astronomers are ferreting out the new targets after the glare of bright, shining stars has frustrated most efforts at visualizing distant worlds, NASA's Jet Propulsion Laboratory (JPL) said.So far, only a handful of distant planets, or exoplanets, have been directly imaged. Small, newborn stars are less blinding, making the planets easier to see, but the fact that these stars are dim means they are hard to find in the first place."Fortunately, the young stars emit more ultraviolet light than their older counterparts, which makes them conspicuous to the ultraviolet-detecting GEE," JPL said in a press release."We've discovered a new technique of using ultraviolet light to search for young, low-mass stars near the Earth," said David Rodriguez, a graduate student of astronomy at University of Californian, Los Angeles. "These young stars make excellent targets for future direct imaging of exoplanets."Young stars, like human children, tend to be a bit unruly -- they spout a greater proportion of energetic X-rays and ultraviolet light than more mature stars. In some cases, X-ray surveys can pick out these youngsters due to the "racket" they cause. However, many smaller, less "noisy" baby stars perfect for exoplanet imaging studies have gone undetected except in the most detailed X-ray surveys. To date, such surveys have covered only a small percentage of the sky, according to JPL in Pasadena, Los Angeles.Rodriguez and his team figured that the GEE, which has scanned about three-quarters of the sky in ultraviolet light, could fill this gap.Astronomers compared readings from the telescope with optical and infrared data to look for the telltale signature of rambunctious junior stars. Follow-up observations of 24 candidates identified in this manner determined that 17 of the stars showed clear signs of youth, validating the team's approach, JPL said."The Galaxy Evolution Explorer can readily select young, low- mass stars that are too faint to turn up in all-sky X-ray surveys, which makes the telescope an incredibly useful tool," Rodriguez said in the release.